Global Basal Cell Carcinoma Market Spotlight Report 2019 Featuring Sun Pharmaceutical, Novartis, Roche, & Valeant Pharmaceuticals – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Basal Cell Carcinoma” report has been added to ResearchAndMarkets.com’s
offering.

This Market Spotlight report covers the basal cell carcinoma market,
comprising key marketed and pipeline drugs, epidemiology, clinical
trials, upcoming events, probability of success, patent information, and
licensing and acquisition deals, as well as presenting drug-specific
revenue forecasts

Key Takeaways:

• The approved drugs in the basal cell carcinoma space target the immune
  system, thymidylate synthase, and hedgehog signaling pathway. The
  majority of these therapies are administered via the topical route,
  with the remainder being oral formulations.
• The majority of industry-sponsored drugs in active clinical
  development for basal cell carcinoma are in Phase II, with two drugs
  in Phase III.
• Therapies in the pipeline for basal cell carcinoma focus on a wide
  variety of targets. These drugs are administered via the topical,
  oral, intravenous, and intratumoral routes.
• High-impact upcoming events for drugs in the basal cell carcinoma
  space comprise topline Phase II trial results for Libtayo, and topline
  Phase III trial results for Ameluz.
• The overall likelihood of approval of a Phase I solid tumors asset is
  5.7%, and the average probability a drug advances from Phase III is
  39.4%. Drugs, on average, take 9.5 years from Phase I to approval,
  compared to 9.2 years in the overall oncology space.
• There have been five licensing and asset acquisition activities
  involving basal cell carcinoma drugs during 2014-19. The $175m
  agreement between Sun Pharmaceutical and Novartis made in December
  2016 for the acquisition of Novartis’s branded oncology product Odomzo
  by Sun Pharmaceutical was the largest deal.
• The distribution of clinical trials across Phase I-IV indicates that
  the majority of trials for basal cell carcinoma have been in the early
  and mid-phases of development, with 81% of trials in Phase I-II, and
  only 19% in Phase III-IV.
• The US has a substantial lead in the number of basal cell carcinoma
  clinical trials globally, while the UK leads the major EU markets.
• Clinical trial activity in the basal cell carcinoma space is dominated
  by completed trials. Roche and Bausch Health have the highest number
  of completed clinical trials for basal cell carcinoma, with 15 and 14
  trials, respectively.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

Basal cell carcinoma subtypes

TREATMENT

Electrodesiccation and curettage (ED&C)

Mohs micrographic surgery

Excisional surgery

Radiation therapy

Cryosurgery

Photodynamic therapy (PDT)

Laser surgery

Pharmacological therapies

EPIDEMIOLOGY

Recent incidence studies

MARKETED DRUGS

PIPELINE DRUGS

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

BIBLIOGRAPHY

Prescription information

APPENDIX

Companies Mentioned

• Sun Pharmaceutical
• Novartis
• Roche
• Valeant Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/201lir

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Skin
Cancer Drugs